Chester County News and Community Website
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported new Phase 3 data showing its investigational oral therapy icotrokinra achieved superior skin clearance compared to deucravacitinib in patients with …
Johnson & Johnson’s Oral Psoriasis Drug Shows Superiority in Phase 3 Trials Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration, seeking approval to update the labeling for …
Johnson & Johnson Seeks FDA Nod for TREMFYA® Label Update Following Psoriatic Arthritis Trial Success Read More SPRING HOUSE, PA — Johnson & Johnson has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for icotrokinra, a once-daily oral peptide therapy targeting the …
Johnson & Johnson Seeks FDA Approval for First Oral IL‑23 Inhibitor to Treat Plaque Psoriasis Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has unveiled new data demonstrating the efficacy of IMAAVY™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG). Presented at the …
Johnson & Johnson Highlights Promising Data on IMAAVY™ for Generalized Myasthenia Gravis Read More SPRING HOUSE, PA — On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & Johnson’s cutting-edge FcRn-blocking antibody treatment for generalized myasthenia gravis (gMG). …
FDA Approves Johnson & Johnson’s IMAAVY for Generalized Myasthenia Gravis Read More SPRING HOUSE, PA — Johnson & Johnson has announced promising results from its Phase 3b APEX trial for TREMFYA® (guselkumab), revealing its effectiveness in treating active psoriatic arthritis (PsA). The …
Johnson & Johnson’s TREMFYA Demonstrates Significant Benefits in Psoriatic Arthritis Study Read More SPRING HOUSE, PA — Johnson & Johnson presented new data on its investigational treatment, nipocalimab, at the 2025 American Academy of Neurology (AAN) Annual Meeting, providing insight into its potential to …
Johnson & Johnson Showcases Promising Data on Nipocalimab for gMG at AAN Annual Meeting Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of adults with moderately to severely …
FDA Approves TREMFYA® for Crohn’s Disease, Offering New Treatment Options Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active …
Johnson & Johnson Reports Positive Study Results for Ulcerative Colitis Treatment Read More SPRING HOUSE, PA — Johnson & Johnson has unveiled new data from Phase 3 trials for icotrokinra (JNJ-2113), an investigational oral peptide targeting the IL-23 receptor, showing significant promise for treating …
Johnson & Johnson Advances Psoriasis Treatment with Promising Icotrokinra Results Read More